232 related articles for article (PubMed ID: 36525238)
1. Evaluating the Patient with Neurotoxicity after Chimeric Antigen Receptor T-cell Therapy.
Fortin Ensign SP; Gaulin C; Hrachova M; Ruff M; Harahsheh E; Vicenti K; Castro J; Munoz J; Rosenthal A; Mrugala MM
Curr Treat Options Oncol; 2022 Dec; 23(12):1845-1860. PubMed ID: 36525238
[TBL] [Abstract][Full Text] [Related]
2. CAR-T Cell Therapy: the Efficacy and Toxicity Balance.
Chohan KL; Siegler EL; Kenderian SS
Curr Hematol Malig Rep; 2023 Apr; 18(2):9-18. PubMed ID: 36763238
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
Brudno JN; Kochenderfer JN
Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
[TBL] [Abstract][Full Text] [Related]
4. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.
Hay KA
Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609
[TBL] [Abstract][Full Text] [Related]
5. Management of Chimeric Antigen Receptor (CAR) T-Cell Toxicities: A Review and Guideline for Emergency Providers.
Gupta R; Roach C; Hryniewicki AT; Vilke GM; Shatsky RA; Coyne CJ
J Emerg Med; 2020 Jul; 59(1):61-74. PubMed ID: 32473867
[TBL] [Abstract][Full Text] [Related]
6. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
Gauthier J; Turtle CJ
Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831
[TBL] [Abstract][Full Text] [Related]
7. INSPIRED Symposium Part 3: Prevention and Management of Pediatric Chimeric Antigen Receptor T Cell-Associated Emergent Toxicities.
McNerney KO; Hsieh EM; Shalabi H; Epperly R; Wolters PL; Hill JA; Gardner R; Talleur AC; Shah NN; Rossoff J
Transplant Cell Ther; 2024 Jan; 30(1):38-55. PubMed ID: 37821079
[TBL] [Abstract][Full Text] [Related]
8. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
[TBL] [Abstract][Full Text] [Related]
9. Management Principles Associated With Cytokine Release Syndrome.
Baer B; Dudley CV; Simons RM
Semin Oncol Nurs; 2019 Oct; 35(5):150931. PubMed ID: 31477411
[TBL] [Abstract][Full Text] [Related]
10. [Toxicity after chimeric antigen receptor T-cell therapy : Overview and management of early and late onset side effects].
Garcia Borrega J; Heindel K; Göreci Y; Warnke C; Onur OA; Kochanek M; Schub N; Ayuk F; Wichmann D; Böll B
Internist (Berl); 2021 Jun; 62(6):611-619. PubMed ID: 34032877
[TBL] [Abstract][Full Text] [Related]
11. Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy.
Hoogland AI; Barata A; Logue J; Kommalapati A; Hyland KA; Nelson AM; Eisel SL; Small BJ; James BW; Christy SM; Bulls HW; Booth-Jones M; Jayani RV; Jain MD; Mokhtari S; Chavez JC; Lazaryan A; Shah BD; Locke FL; Jim HSL
Transplant Cell Ther; 2022 Jun; 28(6):305.e1-305.e9. PubMed ID: 35378330
[TBL] [Abstract][Full Text] [Related]
12. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy.
Sterner RC; Sterner RM
Front Immunol; 2022; 13():879608. PubMed ID: 36081506
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms and strategies for safe chimeric antigen receptor T-cell activity control.
Stock S; Klüver AK; Fertig L; Menkhoff VD; Subklewe M; Endres S; Kobold S
Int J Cancer; 2023 Nov; 153(10):1706-1725. PubMed ID: 37350095
[TBL] [Abstract][Full Text] [Related]
14. Early and Late Toxicities of Chimeric Antigen Receptor T-Cells.
Epperly R; Giordani VM; Mikkilineni L; Shah NN
Hematol Oncol Clin North Am; 2023 Dec; 37(6):1169-1188. PubMed ID: 37349152
[TBL] [Abstract][Full Text] [Related]
15. Toxicities of CD19 CAR-T cell immunotherapy.
Hirayama AV; Turtle CJ
Am J Hematol; 2019 May; 94(S1):S42-S49. PubMed ID: 30784102
[TBL] [Abstract][Full Text] [Related]
16. Next-Generation Implementation of Chimeric Antigen Receptor T-Cell Therapy Using Digital Health.
Banerjee R; Shah N; Dicker AP
JCO Clin Cancer Inform; 2021 Jun; 5():668-678. PubMed ID: 34110929
[TBL] [Abstract][Full Text] [Related]
17. Clinical care of chimeric antigen receptor T-cell patients and managing immune-related adverse effects in the ambulatory and hospitalized setting: a review.
Hays P; Costello C; Asudani D
Future Oncol; 2019 Dec; 15(36):4235-4246. PubMed ID: 31773980
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.
Neelapu SS; Tummala S; Kebriaei P; Wierda W; Gutierrez C; Locke FL; Komanduri KV; Lin Y; Jain N; Daver N; Westin J; Gulbis AM; Loghin ME; de Groot JF; Adkins S; Davis SE; Rezvani K; Hwu P; Shpall EJ
Nat Rev Clin Oncol; 2018 Jan; 15(1):47-62. PubMed ID: 28925994
[TBL] [Abstract][Full Text] [Related]
19. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy.
Schubert ML; Schmitt M; Wang L; Ramos CA; Jordan K; Müller-Tidow C; Dreger P
Ann Oncol; 2021 Jan; 32(1):34-48. PubMed ID: 33098993
[TBL] [Abstract][Full Text] [Related]
20. A review of chimeric antigen receptor T-cells in lymphoma.
Anderson JK; Mehta A
Expert Rev Hematol; 2019 Jul; 12(7):551-561. PubMed ID: 31177852
[No Abstract] [Full Text] [Related]
[Next] [New Search]